Predicted protein targets (top 14)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | MBOAT4 | Q96T53 | 1/20 | 0.46 |
| ▸ | PRMT5 | O14744 | 2/20 | 0.41 |
| ▸ | ACACB | O00763 | 5/20 | 0.41 |
| ▸ | ACACA | Q13085 | 2/20 | 0.41 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.40 |
| ▸ | TP53 | P04637 | 1/20 | 0.39 |
| ▸ | MAOA | P21397 | 1/20 | 0.39 |
| ▸ | MAOB | P27338 | 1/20 | 0.39 |
| ▸ | POLB | P06746 | 1/20 | 0.39 |
| ▸ | KCNH2 | Q12809 | 1/20 | 0.38 |
| ▸ | MCHR1 | Q99705 | 1/20 | 0.38 |
| ▸ | GPR119 | Q8TDV5 | 1/20 | 0.38 |
| ▸ | MEN1 | O00255 | 1/20 | 0.38 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.38 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL16828605 | 0.82 | MBOAT4 (0.44) | MBOAT4ACACBACACAKCNH2MCHR1 | |
| SCHEMBL20339333 | 0.82 | TP53 (0.50) | SMN1; SMN2TP53MAOBPOLBMEN1 | |
| SCHEMBL17317996 | 0.82 | MBOAT4 (0.43) | MBOAT4SMN1; SMN2MEN1KMT2A | |
| SCHEMBL3334225 | 0.80 | MAPK1 (0.47) | SMN1; SMN2MEN1KMT2A | |
| SCHEMBL2635600 | 0.78 | SMN1; SMN2 (0.51) | SMN1; SMN2MAOAMEN1KMT2A | |
| SCHEMBL14677406 | 0.77 | SMN1; SMN2 (0.46) | PRMT5SMN1; SMN2MEN1KMT2A | |
| SCHEMBL1135124 | 0.77 | SMN1; SMN2 (0.46) | SMN1; SMN2POLBMEN1KMT2A | |
| SCHEMBL21323610 | 0.76 | SMN1; SMN2 (0.45) | SMN1; SMN2TP53MEN1KMT2A | |
| SCHEMBL30697582 | 0.76 | PRMT5 (0.60) | PRMT5MAOBMEN1KMT2A | |
| SCHEMBL104202 | 0.76 | MBOAT4 (0.44) | MBOAT4ACACBACACAKCNH2MCHR1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20170305857-A1 | N-ACYLPIPERIDINE ETHER TROPOMYOSIN-RELATED KINASE INHIBITORS | PFIZER LIMITED (UK) | 2017-10-26 | — | — | US | disclosed |
| US-20170305857-A1 | N-ACYLPIPERIDINE ETHER TROPOMYOSIN-RELATED KINASE INHIBITORS | PFIZER LIMITED (UK) | 2017-10-26 | — | — | US | disclosed |
| WO-2015092610-A1 | N-ACYLPIPERIDINE ETHER TROPOMYOSIN-RELATED KINASE INHIBITORS | PFIZER LIMITED (GB) | 2015-06-25 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20170305857-A1 | N-ACYLPIPERIDINE ETHER TROPOMYOSIN-RELATED KINASE INHIBITORS | TNNI3, MUSK, MYLK2 | MBOAT4 1709/4885PRMT5 919/4885ACACB 1106/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.